You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBromocriptine
Accession NumberDB01200  (APRD00622)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionBromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It is indicated for the management of signs and symptoms of Parkinsonian Syndrome. Bromocriptine also inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. It also causes sustained suppression of somatotropin (growth hormone) secretion in some patients with acromegaly. Bromocriptine has been associated with pulmonary fibrosis.
Structure
Thumb
Synonyms
(5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman
(5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione
(5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman
2-Bromo-alpha-ergocryptine
2-Bromo-alpha-ergokryptin
2-Bromo-alpha-ergokryptine
2-bromo-α-ergocryptine
2-bromo-α-ergokryptin
2-bromo-α-ergokryptine
Bromocriptina
Bromocriptinum
Bromocryptine
Bromoergocriptine
Bromoergocryptine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BromocriptineCapsule5 mgOralPharmel Inc1998-09-03Not applicableCanada
BromocriptineTablet2.5 mgOralAa Pharma Inc1994-12-31Not applicableCanada
BromocriptineTablet2.5 mgOralPharmel Inc1998-09-03Not applicableCanada
BromocriptineCapsule5 mgOralAa Pharma Inc1997-01-08Not applicableCanada
Bromocriptine-2.5 - Tab 2.5mgTablet2.5 mgOralPro Doc Limitee1996-12-312010-07-13Canada
Bromocriptine-5Capsule5 mgOralPro Doc Limitee1998-08-112010-07-13Canada
Co Bromocriptine Capsules 5mgCapsule5 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Co Bromocriptine Tablets 2.5mgTablet2.5 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
CyclosetTablet.8 mg/1OralSantarus, Inc.2010-11-15Not applicableUs
Dom-bromocriptineTablet2.5 mgOralDominion Pharmacal1998-10-22Not applicableCanada
Dom-bromocriptineCapsule5 mgOralDominion Pharmacal1998-10-22Not applicableCanada
Nu-bromocriptineTablet2.5 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-bromocriptineCapsule5.0 mgOralNu Pharm IncNot applicableNot applicableCanada
ParlodelCapsule, gelatin coated5 mg/1OralValidus Pharmaceuticals LLC2014-04-28Not applicableUs
ParlodelTablet2.5 mg/1OralValidus Pharmaceuticals LLC2014-06-20Not applicableUs
Parlodel Cap 5mgCapsule5 mgOralNovartis Pharmaceuticals Canada Inc1983-12-312005-09-09Canada
Parlodel Tab 2.5mgTablet2.5 mgOralNovartis Pharmaceuticals Canada Inc1976-12-312007-07-18Canada
PMS-bromocriptineTablet2.5 mgOralPharmascience Inc1998-03-09Not applicableCanada
PMS-bromocriptineCapsule5 mgOralPharmascience Inc1998-03-05Not applicableCanada
Syn-bromocriptine Cap 5mgCapsule5 mgOralSyncare Pharmaceutical Inc.1994-12-311997-08-11Canada
Syn-bromocriptine Tab 2.5mgTablet2.5 mgOralSyncare Pharmaceutical Inc.1994-12-311997-08-11Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bromocriptine MesylateTablet2.5 mg/1OralCarilion Materials Management2008-10-01Not applicableUs
Bromocriptine MesylateTablet2.5 mg/1OralKAISER FOUNDATION HOSPITALS2014-10-10Not applicableUs
Bromocriptine MesylateTablet2.5 mg/1OralSandoz Inc1998-01-13Not applicableUs
Bromocriptine MesylateCapsule5 mg/1OralZydus Pharmaceuticals (USA) Inc.2009-01-23Not applicableUs
Bromocriptine MesylateTablet2.5 mg/1OralMylan Pharmaceuticals Inc.2013-06-06Not applicableUs
Bromocriptine MesylateTablet2.5 mg/1OralPhysicians Total Care, Inc.2006-09-08Not applicableUs
Bromocriptine MesylateCapsule5 mg/1OralAmerican Health Packaging2010-01-132015-12-29Us
Bromocriptine MesylateCapsule5 mg/1OralMylan Pharmaceuticals Inc.2013-06-17Not applicableUs
Bromocriptine MesylateCapsule5 mg/1OralCadila Healthcare Limited2009-01-23Not applicableUs
Bromocriptine MesylateTablet2.5 mg/1OralPaddock Laboratories, LLC2008-10-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Apo-BromocriptineApotex
BagrenSerono (Brazil)
ErgosetNot Available
Parlodel SnaptabsNovartis
PravidelMeda (Germany, Sweden), Novartis (Canada, discontinued)
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Bromocriptine mesylate
ThumbNot applicableDBSALT001209
Categories
UNII3A64E3G5ZO
CAS number25614-03-3
WeightAverage: 654.595
Monoisotopic: 653.221282062
Chemical FormulaC32H40BrN5O5
InChI KeyOZVBMTJYIDMWIL-AYFBDAFISA-N
InChI
InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1
IUPAC Name
(4R,7R)-10-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide
SMILES
[H][C@@]12CCCN1C(=O)[[email protected]](CC(C)C)N1C(=O)[C@](NC(=O)[[email protected]]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C
Pharmacology
IndicationFor the treatment of galactorrhea due to hyperprolactinemia, prolactin-dependent menstrual disorders and infertility, prolactin-secreting adenomas, prolactin-dependent male hypogonadism, as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases, as monotherapy in early Parksinsonian Syndrome or as an adjunct with levodopa in advanced cases with motor complications. Bromocriptine has also been used off-label to treat restless legs syndrome and neuroleptic malignant syndrome.
Structured Indications
PharmacodynamicsBromocriptine stimulates centrally-located dopaminergic receptors resulting in a number of pharmacologic effects. Five dopamine receptor types from two dopaminergic subfamilies have been identified. The dopaminergic D1 receptor subfamily consists of D1 and D5 subreceptors, which are associated with dyskinesias. The dopaminergic D2 receptor subfamily consists of D2, D3 and D4 subreceptors, which are associated with improvement of symptoms of movement disorders. Thus, agonist activity specific for D2 subfamily receptors, primarily D2 and D3 receptor subtypes, are the primary targets of dopaminergic antiparkinsonian agents. It is thought that postsynaptic D2 stimulation is primarily responsible for the antiparkinsonian effect of dopamine agonists, while presynaptic D2 stimulation confers neuroprotective effects. This semisynthetic ergot derivative exhibits potent agonist activity on dopamine D2-receptors. It also exhibits agonist activity (in order of decreasing binding affinity) on 5-hydroxytryptamine (5-HT)1D, dopamine D3, 5-HT1A, 5-HT2A, 5-HT1B, and 5-HT2C receptors, antagonist activity on α2A-adrenergic, α2C, α2B, and dopamine D1 receptors, partial agonist activity at receptor 5-HT2B, and inactivates dopamine D4 and 5-HT7 receptors. Parkinsonian Syndrome manifests when approximately 80% of dopaminergic activity in the nigrostriatal pathway of the brain is lost. As this striatum is involved in modulating the intensity of coordinated muscle activity (e.g. movement, balance, walking), loss of activity may result in dystonia (acute muscle contraction), Parkinsonism (including symptoms of bradykinesia, tremor, rigidity, and flattened affect), akathesia (inner restlessness), tardive dyskinesia (involuntary muscle movements usually associated with long-term loss of dopaminergic activity), and neuroleptic malignant syndrome, which manifests when complete blockage of nigrostriatal dopamine occurs. High dopaminergic activity in the mesolimbic pathway of the brain causes hallucinations and delusions; these side effects of dopamine agonists are manifestations seen in patients with schizophrenia who have overractivity in this area of the brain. The hallucinogenic side effects of dopamine agonists may also be due to 5-HT2A agonism. The tuberoinfundibular pathway of the brain originates in the hypothalamus and terminates in the pituitary gland. In this pathway, dopamine inhibits lactotrophs in anterior pituitary from secreting prolactin. Increased dopaminergic activity in the tuberoinfundibular pathway inhibits prolactin secretion making bromocriptine an effective agent for treating disorders associated with hypersecretion of prolactin. Pulmonary fibrosis may be associated bromocriptine’s agonist activity at 5-HT1B and 5-HT2B receptors.
Mechanism of actionThe dopamine D2 receptor is a 7-transmembrane G-protein coupled receptor associated with Gi proteins. In lactotrophs, stimulation of dopamine D2 receptor causes inhibition of adenylyl cyclase, which decreases intracellular cAMP concentrations and blocks IP3-dependent release of Ca2+ from intracellular stores. Decreases in intracellular calcium levels may also be brought about via inhibition of calcium influx through voltage-gated calcium channels, rather than via inhibition of adenylyl cyclase. Additionally, receptor activation blocks phosphorylation of p42/p44 MAPK and decreases MAPK/ERK kinase phosphorylation. Inhibition of MAPK appears to be mediated by c-Raf and B-Raf-dependent inhibition of MAPK/ERK kinase. Dopamine-stimulated growth hormone release from the pituitary gland is mediated by a decrease in intracellular calcium influx through voltage-gated calcium channels rather than via adenylyl cyclase inhibition. Stimulation of dopamine D2 receptors in the nigrostriatal pathway leads to improvements in coordinated muscle activity in those with movement disorders.
TargetKindPharmacological actionActionsOrganismUniProt ID
D(2) dopamine receptorProteinyes
agonist
HumanP14416 details
D(3) dopamine receptorProteinyes
agonist
HumanP35462 details
5-hydroxytryptamine receptor 1DProteinunknown
agonist
HumanP28221 details
Alpha-2A adrenergic receptorProteinunknown
agonist
HumanP08913 details
5-hydroxytryptamine receptor 1AProteinunknown
agonist
HumanP08908 details
Alpha-2C adrenergic receptorProteinunknown
agonist
HumanP18825 details
Alpha-2B adrenergic receptorProteinunknown
agonist
HumanP18089 details
5-hydroxytryptamine receptor 2BProteinunknown
agonist
HumanP41595 details
D(4) dopamine receptorProteinunknown
antagonist
HumanP21917 details
5-hydroxytryptamine receptor 2AProteinunknown
agonist
HumanP28223 details
5-hydroxytryptamine receptor 1BProteinunknown
agonist
HumanP28222 details
5-hydroxytryptamine receptor 2CProteinunknown
agonist
HumanP28335 details
D(1B) dopamine receptorProteinunknown
agonist
HumanP21918 details
D(1A) dopamine receptorProteinunknown
agonist
HumanP21728 details
Alpha-1A adrenergic receptorProteinunknown
agonist
HumanP35348 details
Alpha-1B adrenergic receptorProteinunknown
agonist
HumanP35368 details
Alpha-1D adrenergic receptorProteinunknown
agonist
HumanP25100 details
5-hydroxytryptamine receptor 7Proteinunknown
antagonist
HumanP34969 details
Related Articles
AbsorptionApproximately 28% of the oral dose is absorbed; however due to a substantial first pass effect, only 6% of the oral dose reaches the systemic circulation unchanged. Bromocriptine and its metabolites appear in the blood as early as 10 minutes following oral administration and peak plasma concentration are reached within 1-1.5 hours. Serum prolactin may be decreased within 2 hours or oral administration with a maximal effect achieved after 8 hours. Growth hormone concentrations in patients with acromegaly is reduced within 1-2 hours with a single oral dose of 2.5 mg and decreased growth hormone concentrations persist for at least 4-5 hours.
Volume of distributionNot Available
Protein binding90-96% bound to serum albumin
Metabolism

Completely metabolized by the liver, primarily by hydrolysis of the amide bond to produce lysergic acid and a peptide fragment, both inactive and non-toxic. Bromocriptine is metabolized by cytochrome P450 3A4 and excreted primarily in the feces via biliary secretion.

Route of eliminationParent drug and metabolites are almost completely excreted via the liver, and only 6% eliminated via the kidney.
Half life2-8 hours
ClearanceNot Available
ToxicitySymptoms of overdosage include nausea, vomiting, and severe hypotension. The most common adverse effects include nausea, headache, vertigo, constipation, light-headedness, abdominal cramps, nasal congestion, diarrhea, and hypotension.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Bromocriptine can be increased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Bromocriptine can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Bromocriptine can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe metabolism of Bromocriptine can be decreased when combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AcebutololBromocriptine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Bromocriptine can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Acetophenazine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Bromocriptine.Approved, Vet Approved
AdrafinilBromocriptine may increase the hypertensive activities of Adrafinil.Withdrawn
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Bromocriptine.Approved
AlbendazoleThe serum concentration of Bromocriptine can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bromocriptine.Approved
AldosteroneThe serum concentration of Bromocriptine can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Bromocriptine can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Bromocriptine can be increased when it is combined with Alfentanil.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Bromocriptine.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Bromocriptine.Approved, Investigational
AlmotriptanBromocriptine may increase the vasoconstricting activities of Almotriptan.Approved, Investigational
AlogliptinThe serum concentration of Bromocriptine can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Bromocriptine can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlprenololBromocriptine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AmantadineThe serum concentration of Bromocriptine can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Bromocriptine.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Bromocriptine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Bromocriptine.Approved
AmineptineAmineptine may decrease the antihypertensive activities of Bromocriptine.Illicit, Withdrawn
Aminohippuric acidThe serum concentration of Bromocriptine can be increased when it is combined with Aminohippuric acid.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Bromocriptine.Approved
AmiodaroneThe metabolism of Bromocriptine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Bromocriptine.Approved, Investigational
AmitrazBromocriptine may increase the hypertensive activities of Amitraz.Vet Approved
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Bromocriptine.Approved
AmlodipineThe serum concentration of Bromocriptine can be increased when it is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Bromocriptine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Bromocriptine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Amperozide.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bromocriptine.Approved, Investigational
AmprenavirThe serum concentration of Bromocriptine can be increased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Bromocriptine can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Bromocriptine.Approved
AnisodamineBromocriptine may increase the hypertensive activities of Anisodamine.Investigational
Antithrombin III humanThe serum concentration of Bromocriptine can be increased when it is combined with Antithrombin III human.Approved
Aop200704Bromocriptine may increase the atrioventricular blocking (AV block) activities of Aop200704.Investigational
ApixabanThe serum concentration of Bromocriptine can be increased when it is combined with Apixaban.Approved
ApomorphineBromocriptine may increase the vasoconstricting activities of Apomorphine.Approved, Investigational
ApraclonidineBromocriptine may increase the hypertensive activities of Apraclonidine.Approved
AprepitantThe serum concentration of Bromocriptine can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Bromocriptine can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineBromocriptine may increase the hypertensive activities of Arbutamine.Approved
ArformoterolBromocriptine may increase the hypertensive activities of Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Bromocriptine can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Bromocriptine.Approved, Investigational
ArotinololBromocriptine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Bromocriptine.Approved, Investigational
AsenapineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Asenapine.Approved
AstemizoleThe serum concentration of Bromocriptine can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Bromocriptine can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Bromocriptine can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololBromocriptine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AtomoxetineThe metabolism of Bromocriptine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Bromocriptine can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Bromocriptine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Azaperone.Vet Approved
AzelastineThe serum concentration of Bromocriptine can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Bromocriptine.Approved
AzithromycinThe serum concentration of Bromocriptine can be increased when it is combined with Azithromycin.Approved
BalsalazideBalsalazide may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Bromocriptine.Experimental
BarbitalBarbital may increase the hypotensive activities of Bromocriptine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Bromocriptine.Approved
BatimastatThe serum concentration of Bromocriptine can be increased when it is combined with Batimastat.Experimental
BefunololBromocriptine may increase the hypertensive activities of Befunolol.Experimental
BenazeprilThe serum concentration of Bromocriptine can be increased when it is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Bromocriptine.Approved
BenmoxinThe metabolism of Bromocriptine can be decreased when combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Benperidol.Investigational
BenzamidineThe serum concentration of Bromocriptine can be increased when it is combined with Benzamidine.Experimental
BenzocaineThe serum concentration of Bromocriptine can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Bromocriptine can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Bromocriptine.Approved, Vet Approved
BetaxololBromocriptine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
BevantololBromocriptine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BexaroteneThe serum concentration of Bromocriptine can be decreased when it is combined with Bexarotene.Approved, Investigational
Bi201335The serum concentration of Bromocriptine can be increased when it is combined with Bi201335.Investigational
BifeprunoxThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bifeprunox.Investigational
BiperidenThe serum concentration of Bromocriptine can be increased when it is combined with Biperiden.Approved
BisoprololBromocriptine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BitolterolBromocriptine may increase the hypertensive activities of Bitolterol.Withdrawn
BivalirudinThe serum concentration of Bromocriptine can be increased when it is combined with Bivalirudin.Approved, Investigational
BlonanserinThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Blonanserin.Approved
BoceprevirThe serum concentration of Bromocriptine can be increased when it is combined with Boceprevir.Approved
BopindololBromocriptine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BortezomibThe metabolism of Bromocriptine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bromocriptine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Bromocriptine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Bromocriptine.Approved
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Bromocriptine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Brexpiprazole.Approved
BrimonidineBromocriptine may increase the hypertensive activities of Brimonidine.Approved
BromperidolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bromperidol.Investigational
BucindololBromocriptine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BufuralolBromocriptine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Bromocriptine.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bupivacaine.Approved, Investigational
BupranololBromocriptine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BuprenorphineThe serum concentration of Bromocriptine can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Bromocriptine.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Bromocriptine.Approved
CabergolineCabergoline may increase the vasoconstricting activities of Bromocriptine.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Bromocriptine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Bromocriptine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Bromocriptine.Approved
CandesartanThe serum concentration of Bromocriptine can be increased when it is combined with Candesartan.Approved
CandoxatrilThe serum concentration of Bromocriptine can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Bromocriptine can be increased when it is combined with Candoxatrilat.Experimental
CaptoprilThe serum concentration of Bromocriptine can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Bromocriptine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Carbetocin.Approved
CarbomycinThe serum concentration of Bromocriptine can be increased when it is combined with Carbomycin.Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Bromocriptine.Approved
CariprazineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Cariprazine.Approved
CaroxazoneThe metabolism of Bromocriptine can be decreased when combined with Caroxazone.Withdrawn
CarteololBromocriptine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolBromocriptine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Bromocriptine can be increased when it is combined with Caspofungin.Approved
CeliprololBromocriptine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Bromocriptine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Bromocriptine.Withdrawn
ChloroquineThe serum concentration of Bromocriptine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Bromocriptine.Approved, Vet Approved
ChlorpromazineThe therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Bromocriptine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Bromocriptine can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Bromocriptine.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Bromocriptine.Approved
CholesterolThe serum concentration of Bromocriptine can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Bromocriptine can be decreased when it is combined with Cholic Acid.Approved
ChymostatinThe serum concentration of Bromocriptine can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Bromocriptine can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Bromocriptine can be increased when it is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cilnidipine.Approved
CimetidineThe serum concentration of Bromocriptine can be decreased when it is combined with Cimetidine.Approved
CinoxacinCinoxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Withdrawn
CiprofloxacinThe serum concentration of Bromocriptine can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CirazolineBromocriptine may increase the hypertensive activities of Cirazoline.Experimental
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Bromocriptine.Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Bromocriptine.Approved
ClarithromycinThe metabolism of Bromocriptine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Bromocriptine can be decreased when combined with Clemastine.Approved
ClenbuterolBromocriptine may increase the hypertensive activities of Clenbuterol.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Bromocriptine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Bromocriptine.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Bromocriptine can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Bromocriptine.Approved, Investigational
ClomipramineClomipramine may decrease the antihypertensive activities of Bromocriptine.Approved, Vet Approved
ClonidineBromocriptine may increase the hypertensive activities of Clonidine.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Bromocriptine.Approved, Nutraceutical
ClotrimazoleThe metabolism of Bromocriptine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Clozapine.Approved
CobicistatThe metabolism of Bromocriptine can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Bromocriptine.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Bromocriptine.Approved
ColforsinThe serum concentration of Bromocriptine can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Bromocriptine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Bromocriptine.Approved
CrizotinibThe metabolism of Bromocriptine can be decreased when combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cyamemazine.Approved
CyclobenzaprineCyclobenzaprine may decrease the antihypertensive activities of Bromocriptine.Approved
CyclophosphamideThe serum concentration of Bromocriptine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Bromocriptine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Bromocriptine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Bromocriptine.Approved
DabrafenibThe serum concentration of Bromocriptine can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Bromocriptine can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Bromocriptine can be increased when it is combined with Dactinomycin.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Bromocriptine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Bromocriptine.Investigational
DarunavirThe serum concentration of Bromocriptine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Bromocriptine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Bromocriptine can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Bromocriptine.Approved
DeferasiroxThe serum concentration of Bromocriptine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Bromocriptine can be decreased when combined with Delavirdine.Approved
dersalazinedersalazine may increase the hypoglycemic activities of Bromocriptine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Desflurane.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Bromocriptine.Approved
DesloratadineThe serum concentration of Bromocriptine can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Desvenlafaxine.Approved
DetomidineBromocriptine may increase the hypertensive activities of Detomidine.Vet Approved
DexamethasoneThe serum concentration of Bromocriptine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineBromocriptine may increase the hypertensive activities of Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Bromocriptine.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Bromocriptine.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Bromocriptine can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Bromocriptine.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Bromocriptine.Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Bromocriptine.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Bromocriptine.Approved
DigoxinThe serum concentration of Bromocriptine can be decreased when it is combined with Digoxin.Approved
DihydroergotamineDihydroergotamine may increase the vasoconstricting activities of Bromocriptine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Bromocriptine.Illicit
DiltiazemThe metabolism of Bromocriptine can be decreased when combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Bromocriptine.Approved
DipivefrinBromocriptine may increase the hypertensive activities of Dipivefrin.Approved
DipyridamoleThe serum concentration of Bromocriptine can be increased when it is combined with Dipyridamole.Approved
DobutamineBromocriptine may increase the hypertensive activities of Dobutamine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Bromocriptine.Approved, Investigational
DolasetronDolasetron may increase the serotonergic activities of Bromocriptine.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Bromocriptine.Approved, Investigational, Vet Approved
DosulepinDosulepin may decrease the antihypertensive activities of Bromocriptine.Approved
DoxazosinThe serum concentration of Bromocriptine can be increased when it is combined with Doxazosin.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Bromocriptine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Bromocriptine.Approved, Investigational
DoxorubicinThe serum concentration of Bromocriptine can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Bromocriptine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Bromocriptine can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Bromocriptine can be decreased when combined with Dronedarone.Approved
DroperidolThe therapeutic efficacy of Droperidol can be decreased when used in combination with Bromocriptine.Approved, Vet Approved
DroxidopaBromocriptine may increase the hypertensive activities of Droxidopa.Approved, Investigational
DuloxetineBromocriptine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EcabetThe serum concentration of Bromocriptine can be increased when it is combined with Ecabet.Approved, Investigational
EcopipamThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Bromocriptine.Approved
EfavirenzThe serum concentration of Bromocriptine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Efonidipine.Approved
ElafinThe serum concentration of Bromocriptine can be increased when it is combined with Elafin.Investigational
ElbasvirThe serum concentration of Bromocriptine can be increased when it is combined with Elbasvir.Approved
EletriptanBromocriptine may increase the vasoconstricting activities of Eletriptan.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Bromocriptine.Approved
EnalaprilThe serum concentration of Bromocriptine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Bromocriptine can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Bromocriptine can be increased when it is combined with Enalkiren.Experimental
EnoxacinEnoxacin may increase the hypoglycemic activities of Bromocriptine.Approved
EnzalutamideThe serum concentration of Bromocriptine can be decreased when it is combined with Enzalutamide.Approved
EphedrineBromocriptine may increase the hypertensive activities of Ephedrine.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Bromocriptine.Approved, Investigational
EpinephrineBromocriptine may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Bromocriptine.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bromocriptine.Approved
Ergoloid mesylateErgoloid mesylate may increase the vasoconstricting activities of Bromocriptine.Approved
ErgonovineErgonovine may increase the vasoconstricting activities of Bromocriptine.Approved
ErgotamineBromocriptine may increase the hypertensive activities of Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Bromocriptine.Approved, Investigational
ErythromycinThe serum concentration of Bromocriptine can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Bromocriptine.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Bromocriptine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Bromocriptine.Investigational
EsmololBromocriptine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Bromocriptine.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Bromocriptine can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Bromocriptine can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Bromocriptine can be decreased when it is combined with Estrone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Bromocriptine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Bromocriptine.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Bromocriptine.Approved
EtilefrineBromocriptine may increase the hypertensive activities of Etilefrine.Withdrawn
EtoperidoneEtoperidone may increase the hypoglycemic activities of Bromocriptine.Approved
EtoposideThe serum concentration of Bromocriptine can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Bromocriptine can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Bromocriptine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Bromocriptine.Approved
FelodipineThe serum concentration of Bromocriptine can be increased when it is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fenoldopam.Approved
FenoterolBromocriptine may increase the hypertensive activities of Fenoterol.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bromocriptine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Bromocriptine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Bromocriptine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Bromocriptine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fimasartan.Approved
FleroxacinFleroxacin may increase the hypoglycemic activities of Bromocriptine.Approved
FluconazoleThe metabolism of Bromocriptine can be decreased when combined with Fluconazole.Approved
FlumequineFlumequine may increase the hypoglycemic activities of Bromocriptine.Withdrawn
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Bromocriptine.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Bromocriptine.Approved, Illicit
FlupentixolThe therapeutic efficacy of Flupentixol can be decreased when used in combination with Bromocriptine.Approved, Withdrawn
FluphenazineThe therapeutic efficacy of Fluphenazine can be decreased when used in combination with Bromocriptine.Approved
FlurazepamThe serum concentration of Bromocriptine can be increased when it is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluspirilene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Bromocriptine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Bromocriptine.Approved, Investigational
FormoterolBromocriptine may increase the hypertensive activities of Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Bromocriptine can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Bromocriptine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Bromocriptine can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Bromocriptine can be increased when combined with Fosphenytoin.Approved
FrovatriptanBromocriptine may increase the vasoconstricting activities of Frovatriptan.Approved, Investigational
FurazolidoneThe metabolism of Bromocriptine can be decreased when combined with Furazolidone.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Bromocriptine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Bromocriptine can be increased when it is combined with Fusidic Acid.Approved
GabexateThe serum concentration of Bromocriptine can be increased when it is combined with Gabexate.Investigational
GarenoxacinGarenoxacin may increase the hypoglycemic activities of Bromocriptine.Investigational
GatifloxacinGatifloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Bromocriptine.Approved, Investigational
GeldanamycinThe serum concentration of Bromocriptine can be increased when it is combined with Geldanamycin.Experimental
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Bromocriptine.Approved
GemifloxacinGemifloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
GenisteinThe serum concentration of Bromocriptine can be increased when it is combined with Genistein.Investigational
GlyburideThe serum concentration of Bromocriptine can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Bromocriptine can be increased when it is combined with Glycerol.Experimental
GM6001The serum concentration of Bromocriptine can be increased when it is combined with GM6001.Experimental
Gramicidin DThe serum concentration of Bromocriptine can be increased when it is combined with Gramicidin D.Approved
GranisetronGranisetron may increase the serotonergic activities of Bromocriptine.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Bromocriptine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Bromocriptine.Withdrawn
GuanabenzBromocriptine may increase the hypertensive activities of Guanabenz.Approved
GuanfacineBromocriptine may increase the hypertensive activities of Guanfacine.Approved, Investigational
HaloperidolThe therapeutic efficacy of Haloperidol can be decreased when used in combination with Bromocriptine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Halothane.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Bromocriptine.Approved
HexoprenalineBromocriptine may increase the hypertensive activities of Hexoprenaline.Approved, Withdrawn
HigenamineBromocriptine may increase the hypertensive activities of Higenamine.Investigational
HirulogThe serum concentration of Bromocriptine can be increased when it is combined with Hirulog.Experimental
HydracarbazineThe metabolism of Bromocriptine can be decreased when combined with Hydracarbazine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Bromocriptine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Bromocriptine.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Bromocriptine.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Hydroflumethiazide.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Bromocriptine.Approved
IdelalisibThe serum concentration of Bromocriptine can be increased when it is combined with Idelalisib.Approved
idraparinuxThe serum concentration of Bromocriptine can be increased when it is combined with idraparinux.Investigational
IloperidoneThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Iloprost.Approved, Investigational
ImatinibThe metabolism of Bromocriptine can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Bromocriptine can be increased when it is combined with Imidapril.Investigational
ImipramineImipramine may decrease the antihypertensive activities of Bromocriptine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Bromocriptine.Approved
IndalpineIndalpine may increase the hypoglycemic activities of Bromocriptine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Bromocriptine.Approved
IndenololBromocriptine may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Bromocriptine can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Bromocriptine can be increased when it is combined with Indomethacin.Approved, Investigational
IndoraminThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Indoramin.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Bromocriptine.Approved
IproclozideThe metabolism of Bromocriptine can be decreased when combined with Iproclozide.Withdrawn
IproniazidThe metabolism of Bromocriptine can be decreased when combined with Iproniazid.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Bromocriptine.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Bromocriptine.Approved, Investigational
IsavuconazoniumThe metabolism of Bromocriptine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe metabolism of Bromocriptine can be decreased when combined with Isocarboxazid.Approved
IsoetarineBromocriptine may increase the hypertensive activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Isoflurane.Approved, Vet Approved
IsoflurophateThe serum concentration of Bromocriptine can be increased when it is combined with Isoflurophate.Approved, Withdrawn
IsoprenalineBromocriptine may increase the hypertensive activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Bromocriptine.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Bromocriptine.Approved
IsoxsuprineBromocriptine may increase the hypertensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Bromocriptine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Bromocriptine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Bromocriptine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Bromocriptine.Approved, Vet Approved
IxazomibThe serum concentration of Bromocriptine can be increased when it is combined with Ixazomib.Approved
JosamycinThe serum concentration of Bromocriptine can be increased when it is combined with Josamycin.Approved
KetamineThe serum concentration of Bromocriptine can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Bromocriptine.Approved
KetoconazoleThe metabolism of Bromocriptine can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe serum concentration of Bromocriptine can be increased when it is combined with Kitasamycin.Experimental
LabetalolBromocriptine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Bromocriptine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Bromocriptine.Approved, Investigational
LanreotideThe serum concentration of Bromocriptine can be increased when it is combined with Lanreotide.Approved
LansoprazoleThe serum concentration of Bromocriptine can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Bromocriptine can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Bromocriptine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Bromocriptine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Bromocriptine.Approved
LepirudinThe serum concentration of Bromocriptine can be increased when it is combined with Lepirudin.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lercanidipine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Bromocriptine.Approved, Investigational
LevobunololLevobunolol may increase the vasoconstricting activities of Bromocriptine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Levobupivacaine.Approved
LevodopaBromocriptine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Bromocriptine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Levomilnacipran.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Levosimendan.Approved, Investigational
LevothyroxineThe serum concentration of Bromocriptine can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Bromocriptine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Bromocriptine can be increased when it is combined with Linagliptin.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Bromocriptine.Approved, Investigational
LiothyronineThe serum concentration of Bromocriptine can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Bromocriptine can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Bromocriptine can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideBromocriptine may increase the vasoconstricting activities of Lisuride.Approved
LithiumThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lithium.Approved
LofexidineBromocriptine may increase the hypertensive activities of Lofexidine.Approved, Investigational
LomefloxacinLomefloxacin may increase the hypoglycemic activities of Bromocriptine.Approved
LomitapideThe serum concentration of Bromocriptine can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Bromocriptine.Approved
LopinavirThe serum concentration of Bromocriptine can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Bromocriptine can be increased when it is combined with Loratadine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Bromocriptine.Approved
LosartanThe serum concentration of Bromocriptine can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Bromocriptine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe therapeutic efficacy of Loxapine can be decreased when used in combination with Bromocriptine.Approved
Lu AA21004Bromocriptine may increase the vasoconstricting activities of Lu AA21004.Investigational
LuliconazoleThe serum concentration of Bromocriptine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Bromocriptine can be decreased when it is combined with Lumacaftor.Approved
LumateperoneThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Lumateperone.Investigational
LurasidoneThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Lurasidone.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Bromocriptine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Bromocriptine.Approved
MebanazineThe metabolism of Bromocriptine can be decreased when combined with Mebanazine.Withdrawn
MebendazoleThe serum concentration of Bromocriptine can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Bromocriptine.Approved
MedetomidineBromocriptine may increase the hypertensive activities of Medetomidine.Vet Approved
MefloquineThe serum concentration of Bromocriptine can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Bromocriptine can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelperoneThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Melperone.Approved
MephentermineBromocriptine may increase the hypertensive activities of Mephentermine.Approved
MeprobamateThe serum concentration of Bromocriptine can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineMesalazine may increase the hypoglycemic activities of Bromocriptine.Approved
MesoridazineThe therapeutic efficacy of Mesoridazine can be decreased when used in combination with Bromocriptine.Approved
MetaraminolBromocriptine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Bromocriptine.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Bromocriptine.Approved
MethohexitalMethohexital may increase the hypotensive activities of Bromocriptine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Bromocriptine.Approved
MethotrimeprazineThe therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Bromocriptine.Approved
MethoxamineBromocriptine may increase the hypertensive activities of Methoxamine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bromocriptine.Approved
MethyldopaBromocriptine may increase the hypertensive activities of Methyldopa.Approved
Methylene blueThe metabolism of Bromocriptine can be decreased when combined with Methylene blue.Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Bromocriptine.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Bromocriptine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Bromocriptine.Approved, Vet Approved
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Bromocriptine.Approved
MetipranololMetipranolol may increase the vasoconstricting activities of Bromocriptine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Metoclopramide.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Bromocriptine.Approved
MetoprololBromocriptine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MianserinThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Mianserin.Approved
MibefradilThe serum concentration of Bromocriptine can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Bromocriptine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Bromocriptine can be decreased when it is combined with Midazolam.Approved, Illicit
MidodrineBromocriptine may increase the hypertensive activities of Midodrine.Approved
MifepristoneThe serum concentration of Bromocriptine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Milnacipran.Approved
MinaprineThe metabolism of Bromocriptine can be decreased when combined with Minaprine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Bromocriptine.Approved
MirabegronBromocriptine may increase the hypertensive activities of Mirabegron.Approved
MirtazapineMirtazapine may decrease the antihypertensive activities of Bromocriptine.Approved
MitomycinThe serum concentration of Bromocriptine can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Bromocriptine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Bromocriptine can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideThe metabolism of Bromocriptine can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Bromocriptine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Bromocriptine can be increased when it is combined with Moexipril.Approved
MolindoneThe therapeutic efficacy of Molindone can be decreased when used in combination with Bromocriptine.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Bromocriptine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Bromocriptine.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Bromocriptine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nabilone.Approved, Investigational
NadololBromocriptine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NafamostatThe serum concentration of Bromocriptine can be increased when it is combined with Nafamostat.Investigational
NafcillinThe serum concentration of Bromocriptine can be decreased when it is combined with Nafcillin.Approved
Nalidixic AcidNalidixic Acid may increase the hypoglycemic activities of Bromocriptine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Bromocriptine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Bromocriptine.Approved, Vet Approved
NaltrexoneThe serum concentration of Bromocriptine can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaphazolineBromocriptine may increase the hypertensive activities of Naphazoline.Approved
NaratriptanBromocriptine may increase the vasoconstricting activities of Naratriptan.Approved, Investigational
NaringeninThe serum concentration of Bromocriptine can be increased when it is combined with Naringenin.Experimental
NCX 4016The serum concentration of Bromocriptine can be increased when it is combined with NCX 4016.Investigational
NebivololBromocriptine may increase the hypertensive activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Bromocriptine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Bromocriptine can be increased when it is combined with Nelfinavir.Approved
NemonoxacinNemonoxacin may increase the hypoglycemic activities of Bromocriptine.Investigational
NeostigmineThe serum concentration of Bromocriptine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Bromocriptine.Approved, Investigational
NetupitantThe serum concentration of Bromocriptine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Bromocriptine can be increased when combined with Nevirapine.Approved
NialamideThe metabolism of Bromocriptine can be decreased when combined with Nialamide.Withdrawn
NicardipineThe serum concentration of Bromocriptine can be increased when it is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Bromocriptine.Approved
NifedipineThe serum concentration of Bromocriptine can be decreased when it is combined with Nifedipine.Approved
NilotinibThe metabolism of Bromocriptine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Bromocriptine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Bromocriptine.Approved
NisoldipineThe serum concentration of Bromocriptine can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Bromocriptine can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Bromocriptine can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nitric Oxide.Approved
NitroaspirinThe serum concentration of Bromocriptine can be increased when it is combined with Nitroaspirin.Investigational
NitroglycerinBromocriptine may decrease the vasodilatory activities of Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Bromocriptine.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Bromocriptine.Approved
NorepinephrineBromocriptine may increase the hypertensive activities of Norepinephrine.Approved
NorethisteroneThe serum concentration of Bromocriptine can be decreased when it is combined with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the hypoglycemic activities of Bromocriptine.Approved
NortriptylineNortriptyline may decrease the antihypertensive activities of Bromocriptine.Approved
NylidrinBromocriptine may increase the hypertensive activities of Nylidrin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Obinutuzumab.Approved
OctamoxinThe metabolism of Bromocriptine can be decreased when combined with Octamoxin.Withdrawn
OctreotideThe serum concentration of Bromocriptine can be increased when it is combined with Octreotide.Approved, Investigational
OfloxacinOfloxacin may increase the hypoglycemic activities of Bromocriptine.Approved
OlanzapineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Bromocriptine can be decreased when combined with Olaparib.Approved
OleandomycinThe serum concentration of Bromocriptine can be increased when it is combined with Oleandomycin.Vet Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bromocriptine.Approved, Investigational
OlodaterolBromocriptine may increase the hypertensive activities of Olodaterol.Approved
OlsalazineOlsalazine may increase the hypoglycemic activities of Bromocriptine.Approved
OmapatrilatThe serum concentration of Bromocriptine can be increased when it is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Bromocriptine.Approved
OmeprazoleThe serum concentration of Bromocriptine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the serotonergic activities of Bromocriptine.Approved
OpipramolOpipramol may decrease the antihypertensive activities of Bromocriptine.Investigational
OrciprenalineBromocriptine may increase the hypertensive activities of Orciprenaline.Approved
OsanetantThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Bromocriptine can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Bromocriptine can be increased when it is combined with Otamixaban.Investigational
OxandroloneOxandrolone may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
OxprenololBromocriptine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
OxymetazolineBromocriptine may increase the hypertensive activities of Oxymetazoline.Approved
OxymetholoneOxymetholone may increase the hypoglycemic activities of Bromocriptine.Approved, Illicit
P-NitrophenolThe serum concentration of Bromocriptine can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Bromocriptine can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Bromocriptine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Paliperidone.Approved
Palmitic AcidThe serum concentration of Bromocriptine can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronPalonosetron may increase the serotonergic activities of Bromocriptine.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Bromocriptine.Approved, Investigational
PantoprazoleThe serum concentration of Bromocriptine can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Bromocriptine.Approved
PargylineThe metabolism of Bromocriptine can be decreased when combined with Pargyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Bromocriptine.Approved, Investigational
PasireotideThe serum concentration of Bromocriptine can be increased when it is combined with Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Bromocriptine.Approved
PazufloxacinPazufloxacin may increase the hypoglycemic activities of Bromocriptine.Investigational
PefloxacinPefloxacin may increase the hypoglycemic activities of Bromocriptine.Approved
PegvisomantPegvisomant may increase the hypoglycemic activities of Bromocriptine.Approved
PenbutololBromocriptine may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PentobarbitalThe metabolism of Bromocriptine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Perazine.Investigational
PergolideBromocriptine may increase the vasoconstricting activities of Pergolide.Approved, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Bromocriptine can be increased when it is combined with Perindopril.Approved
PerospironeThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Perospirone.Approved
PerphenazineThe therapeutic efficacy of Perphenazine can be decreased when used in combination with Bromocriptine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Bromocriptine.Approved
PhenelzineThe metabolism of Bromocriptine can be decreased when combined with Phenelzine.Approved
PheniprazineThe metabolism of Bromocriptine can be decreased when combined with Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Bromocriptine can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Phenoxybenzamine.Approved
PhenoxypropazineThe metabolism of Bromocriptine can be decreased when combined with Phenoxypropazine.Withdrawn
PhentolamineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Phentolamine.Approved
PhenylephrineBromocriptine may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineBromocriptine may increase the hypertensive activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Bromocriptine can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Bromocriptine can be increased when it is combined with Phosphoramidon.Experimental
PimavanserinThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Pimavanserin.Investigational
PimozideThe therapeutic efficacy of Pimozide can be decreased when used in combination with Bromocriptine.Approved
PindololBromocriptine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Pipotiazine.Approved
PirbuterolBromocriptine may increase the hypertensive activities of Pirbuterol.Approved
PirlindoleThe metabolism of Bromocriptine can be decreased when combined with Pirlindole.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Bromocriptine.Approved
PivhydrazineThe metabolism of Bromocriptine can be decreased when combined with Pivhydrazine.Withdrawn
Platelet Activating FactorThe serum concentration of Bromocriptine can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Bromocriptine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Bromocriptine.Approved
PosaconazoleThe metabolism of Bromocriptine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololBromocriptine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Bromocriptine.Approved
PrazosinThe serum concentration of Bromocriptine can be increased when it is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Bromocriptine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Bromocriptine.Approved, Vet Approved
PrimidoneThe metabolism of Bromocriptine can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Bromocriptine can be increased when it is combined with Prinomastat.Investigational
ProbenecidThe serum concentration of Bromocriptine can be increased when it is combined with Probenecid.Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Bromocriptine.Approved
ProcaterolBromocriptine may increase the hypertensive activities of Procaterol.Approved
ProchlorperazineThe therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Bromocriptine.Approved, Vet Approved
ProgesteroneThe serum concentration of Bromocriptine can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe therapeutic efficacy of Promazine can be decreased when used in combination with Bromocriptine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Bromocriptine.Approved
PropafenoneThe serum concentration of Bromocriptine can be increased when it is combined with Propafenone.Approved
PropericiazineThe therapeutic efficacy of Propericiazine can be decreased when used in combination with Bromocriptine.Approved
PropofolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololBromocriptine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Prothipendyl.Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Bromocriptine.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Bromocriptine.Approved
PrulifloxacinPrulifloxacin may increase the hypoglycemic activities of Bromocriptine.Investigational
PRX-00023Bromocriptine may increase the vasoconstricting activities of PRX-00023.Investigational
PseudoephedrineBromocriptine may increase the hypertensive activities of Pseudoephedrine.Approved
QuercetinThe serum concentration of Bromocriptine can be increased when it is combined with Quercetin.Experimental
QuetiapineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Quetiapine.Approved
QuinacrineThe serum concentration of Bromocriptine can be increased when it is combined with Quinacrine.Approved
QuinaprilThe serum concentration of Bromocriptine can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Bromocriptine can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Bromocriptine can be increased when it is combined with Quinine.Approved
RacecadotrilThe serum concentration of Bromocriptine can be increased when it is combined with Racecadotril.Investigational
RacepinephrineBromocriptine may increase the hypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Raclopride.Investigational
RactopamineBromocriptine may increase the hypertensive activities of Ractopamine.Vet Approved
RamiprilThe serum concentration of Bromocriptine can be increased when it is combined with Ramipril.Approved
RanitidineThe serum concentration of Bromocriptine can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Bromocriptine.Approved, Investigational
RasagilineThe metabolism of Bromocriptine can be decreased when combined with Rasagiline.Approved
ReboxetineThe serum concentration of Bromocriptine can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Bromocriptine can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Remifentanil.Approved
RemikirenThe serum concentration of Bromocriptine can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Remoxipride.Approved, Withdrawn
ReserpineThe serum concentration of Bromocriptine can be decreased when it is combined with Reserpine.Approved
RifabutinThe metabolism of Bromocriptine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Bromocriptine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Bromocriptine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Bromocriptine.Approved, Investigational
RilmenidineBromocriptine may increase the hypertensive activities of Rilmenidine.Investigational
RilpivirineThe serum concentration of Bromocriptine can be increased when it is combined with Rilpivirine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Bromocriptine.Approved
RisperidoneBromocriptine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ritanserin.Investigational
RitobegronBromocriptine may increase the hypertensive activities of Ritobegron.Investigational
RitodrineBromocriptine may increase the hypertensive activities of Ritodrine.Approved
RitonavirThe serum concentration of Bromocriptine can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Bromocriptine can be increased when it is combined with Rivaroxaban.Approved
RizatriptanBromocriptine may increase the vasoconstricting activities of Rizatriptan.Approved
RolapitantThe serum concentration of Bromocriptine can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Bromocriptine.Approved, Investigational
RomifidineBromocriptine may increase the hypertensive activities of Romifidine.Vet Approved
RopiniroleBromocriptine may increase the vasoconstricting activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ropivacaine.Approved
RosoxacinRosoxacin may increase the hypoglycemic activities of Bromocriptine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Rotigotine.Approved
RoxithromycinThe serum concentration of Bromocriptine can be increased when it is combined with Roxithromycin.Approved, Withdrawn
RP5063The therapeutic efficacy of Bromocriptine can be decreased when used in combination with RP5063.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sacubitril.Approved
SafrazineThe metabolism of Bromocriptine can be decreased when combined with Safrazine.Withdrawn
SalbutamolBromocriptine may increase the hypertensive activities of Salbutamol.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Bromocriptine.Approved, Vet Approved
SalmeterolBromocriptine may increase the hypertensive activities of Salmeterol.Approved
SaquinavirThe serum concentration of Bromocriptine can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Bromocriptine can be increased when it is combined with Saxagliptin.Approved
ScopolamineThe serum concentration of Bromocriptine can be increased when it is combined with Scopolamine.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Bromocriptine.Approved, Vet Approved
SelegilineThe metabolism of Bromocriptine can be decreased when combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Bromocriptine.Approved
SertindoleThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Bromocriptine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Bromocriptine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Bromocriptine.Approved
SiltuximabThe serum concentration of Bromocriptine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Bromocriptine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Bromocriptine can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Bromocriptine can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Bromocriptine can be increased when it is combined with Sitagliptin.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Bromocriptine.Approved
SolabegronBromocriptine may increase the hypertensive activities of Solabegron.Investigational
SolithromycinThe serum concentration of Bromocriptine can be increased when it is combined with Solithromycin.Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Bromocriptine.Approved, Investigational
SotalolBromocriptine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Bromocriptine.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Bromocriptine.Experimental
SpiraprilThe serum concentration of Bromocriptine can be increased when it is combined with Spirapril.Approved
SpironolactoneThe serum concentration of Bromocriptine can be increased when it is combined with Spironolactone.Approved
SR 58611Bromocriptine may increase the hypertensive activities of SR 58611.Investigational
St. John's WortThe serum concentration of Bromocriptine can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololStanozolol may increase the hypoglycemic activities of Bromocriptine.Approved, Vet Approved
StaurosporineThe serum concentration of Bromocriptine can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Bromocriptine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Streptokinase.Approved
StreptozocinThe serum concentration of Bromocriptine can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sufentanil.Approved, Investigational
SulfinpyrazoneThe serum concentration of Bromocriptine can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Bromocriptine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sulpiride.Approved
SumatriptanBromocriptine may increase the vasoconstricting activities of Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Bromocriptine can be increased when it is combined with Sunitinib.Approved, Investigational
SynephrineBromocriptine may increase the hypertensive activities of Synephrine.Experimental
TacrineThe serum concentration of Bromocriptine can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Bromocriptine can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Bromocriptine can be decreased when it is combined with Tamoxifen.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tamsulosin.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tapentadol.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Bromocriptine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Bromocriptine.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Bromocriptine.Approved
TelaprevirThe serum concentration of Bromocriptine can be increased when it is combined with Telaprevir.Approved
TelithromycinThe metabolism of Bromocriptine can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Bromocriptine can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinTemafloxacin may increase the hypoglycemic activities of Bromocriptine.Withdrawn
TemocaprilThe serum concentration of Bromocriptine can be increased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Bromocriptine.Approved
TerazosinThe serum concentration of Bromocriptine can be increased when it is combined with Terazosin.Approved
TerbutalineBromocriptine may increase the hypertensive activities of Terbutaline.Approved
TerfenadineThe serum concentration of Bromocriptine can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Bromocriptine can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Bromocriptine can be increased when it is combined with Testosterone.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Bromocriptine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Bromocriptine.Approved, Vet Approved
ThioproperazineThe therapeutic efficacy of Thioproperazine can be decreased when used in combination with Bromocriptine.Approved
ThioridazineThe therapeutic efficacy of Thioridazine can be decreased when used in combination with Bromocriptine.Approved
ThiorphanThe serum concentration of Bromocriptine can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThe therapeutic efficacy of Thiothixene can be decreased when used in combination with Bromocriptine.Approved
TianeptineTianeptine may decrease the antihypertensive activities of Bromocriptine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Bromocriptine.Approved
TiclopidineThe metabolism of Bromocriptine can be decreased when combined with Ticlopidine.Approved
TimololBromocriptine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TipranavirThe serum concentration of Bromocriptine can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Bromocriptine.Approved
TocilizumabThe serum concentration of Bromocriptine can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe metabolism of Bromocriptine can be decreased when combined with Toloxatone.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Bromocriptine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Bromocriptine.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Bromocriptine.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Bromocriptine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Bromocriptine.Approved, Investigational
TrandolaprilThe serum concentration of Bromocriptine can be increased when it is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe metabolism of Bromocriptine can be decreased when combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Bromocriptine can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Bromocriptine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Bromocriptine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Bromocriptine.Approved
TrifluoperazineThe therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Bromocriptine.Approved
TriflupromazineThe serum concentration of Bromocriptine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Bromocriptine can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may decrease the antihypertensive activities of Bromocriptine.Approved
TroleandomycinThe serum concentration of Bromocriptine can be increased when it is combined with Troleandomycin.Approved
TropisetronTropisetron may increase the serotonergic activities of Bromocriptine.Investigational
TrovafloxacinTrovafloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Withdrawn
TulobuterolBromocriptine may increase the hypertensive activities of Tulobuterol.Investigational
TylosinThe serum concentration of Bromocriptine can be increased when it is combined with Tylosin.Vet Approved
UbenimexThe serum concentration of Bromocriptine can be increased when it is combined with Ubenimex.Experimental
UlinastatinThe serum concentration of Bromocriptine can be increased when it is combined with Ulinastatin.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Bromocriptine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Bromocriptine.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Bromocriptine.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Bromocriptine.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Bromocriptine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Bromocriptine.Approved
VerapamilThe metabolism of Bromocriptine can be decreased when combined with Verapamil.Approved
VilazodoneBromocriptine may increase the vasoconstricting activities of Vilazodone.Approved
VildagliptinThe serum concentration of Bromocriptine can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe serum concentration of Bromocriptine can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Bromocriptine.Approved, Investigational
VincristineThe serum concentration of Bromocriptine can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Bromocriptine can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Bromocriptine.Approved
VoriconazoleThe metabolism of Bromocriptine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineBromocriptine may increase the vasoconstricting activities of Vortioxetine.Approved
XimelagatranThe serum concentration of Bromocriptine can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineBromocriptine may increase the hypertensive activities of Xylazine.Vet Approved
YM-178Bromocriptine may increase the hypertensive activities of YM-178.Investigational
Ym150The serum concentration of Bromocriptine can be increased when it is combined with Ym150.Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Bromocriptine.Approved
ZimelidineThe serum concentration of Bromocriptine can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Ziprasidone.Approved
ZolmitriptanBromocriptine may increase the vasoconstricting activities of Zolmitriptan.Approved, Investigational
ZotepineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Zotepine.Approved
ZuclopenthixolThe therapeutic efficacy of Zuclopenthixol can be decreased when used in combination with Bromocriptine.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.
References
Synthesis Reference

Luigi Moro, Achille Fiori, Alberto Natali, “Processes for the preparation of pharmaceutical compositions containing bromocriptine having high stability and related products.” U.S. Patent US5066495, issued May, 1988.

US5066495
General References
  1. Banihashemi B, Albert PR: Dopamine-D2S receptor inhibition of calcium influx, adenylyl cyclase, and mitogen-activated protein kinase in pituitary cells: distinct Galpha and Gbetagamma requirements. Mol Endocrinol. 2002 Oct;16(10):2393-404. [PubMed:12351703 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
  4. Malgaroli A, Vallar L, Elahi FR, Pozzan T, Spada A, Meldolesi J: Dopamine inhibits cytosolic Ca2+ increases in rat lactotroph cells. Evidence of a dual mechanism of action. J Biol Chem. 1987 Oct 15;262(29):13920-7. [PubMed:2443499 ]
  5. Nishina Y, Takano K, Yasufuku-Takano J, Teramoto A, Fujita T: Mechanism of D(2) agonist-induced inhibition of GH secretion from human GH-secreting adenoma cells. Endocr J. 2005 Dec;52(6):775-9. [PubMed:16410672 ]
  6. Vallar L, Meldolesi J: Mechanisms of signal transduction at the dopamine D2 receptor. Trends Pharmacol Sci. 1989 Feb;10(2):74-7. [PubMed:2655242 ]
  7. Vallar L, Vicentini LM, Meldolesi J: Inhibition of inositol phosphate production is a late, Ca2+-dependent effect of D2 dopaminergic receptor activation in rat lactotroph cells. J Biol Chem. 1988 Jul 25;263(21):10127-34. [PubMed:2839476 ]
External Links
ATC CodesG02CB01N04BC01
AHFS Codes
  • 28:36.20.04
PDB EntriesNot Available
FDA labelDownload (105 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.915
Blood Brain Barrier-0.9845
Caco-2 permeable-0.6618
P-glycoprotein substrateSubstrate0.8881
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterNon-inhibitor0.837
CYP450 2C9 substrateNon-substrate0.8345
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7454
CYP450 1A2 substrateNon-inhibitor0.9031
CYP450 2C9 inhibitorInhibitor0.8326
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5149
Ames testNon AMES toxic0.7879
CarcinogenicityNon-carcinogens0.9353
BiodegradationNot ready biodegradable0.9973
Rat acute toxicity2.7499 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9313
hERG inhibition (predictor II)Inhibitor0.5
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral5 mg
TabletOral2.5 mg
CapsuleOral5 mg/1
TabletOral2.5 mg/1
TabletOral.8 mg/1
CapsuleOral5.0 mg
Capsule, gelatin coatedOral5 mg/1
Prices
Unit descriptionCostUnit
Bromocriptine mesylate powd384.03USD g
Parlodel 5 mg capsule9.25USD capsule
Parlodel 2.5 mg tablet5.64USD tablet
Bromocriptine Mesylate 5 mg capsule5.21USD capsule
Bromocriptine Mesylate 2.5 mg tablet2.28USD tablet
Bromocriptine 2.5 mg tablet2.18USD tablet
Apo-Bromocriptine 5 mg Capsule1.02USD capsule
Pms-Bromocriptine 5 mg Capsule1.02USD capsule
Apo-Bromocriptine 2.5 mg Tablet0.57USD tablet
Pms-Bromocriptine 2.5 mg Tablet0.57USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5468755 No1992-11-212012-11-21Us
US5716957 No1995-02-102015-02-10Us
US7888310 No2003-07-252023-07-25Us
US8137992 No2003-07-252023-07-25Us
US8137993 No2003-07-252023-07-25Us
US8137994 No2003-07-252023-07-25Us
US8431155 No2012-04-302032-04-30Us
US8613947 No2012-04-302032-04-30Us
US8877708 No2010-06-072030-06-07Us
US9192576 No2012-04-302032-04-30Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point215-218Fluckiger, E.,Troxler, F. and Hofmann, A,; US. Patent 3,752,814; August 14, 1973; assigned to Sandoz Ltd., Switzerland. Fluckiger, E., Troxler, F. and Hofmann, A.; U.S. Patent 3,752,888; August 14, 1973; assigned to Sandoz Ltd., Switzerland.
logP3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0858 mg/mLALOGPS
logP3.2ALOGPS
logP3.89ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)9.68ChemAxon
pKa (Strongest Basic)6.71ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.21 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity165.51 m3·mol-1ChemAxon
Polarizability66.44 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as ergopeptines. These are ergoline derivatives that contain a tripeptide structure attached to the basic ergoline ring in the same location as the amide group of the lysergic acid derivatives.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassErgoline and derivatives
Sub ClassLysergic acids and derivatives
Direct ParentErgopeptines
Alternative Parents
Substituents
  • Hybrid peptide
  • Ergopeptine
  • Lysergic acid amide
  • Indoloquinoline
  • Benzoquinoline
  • Quinoline-3-carboxamide
  • Pyrroloquinoline
  • N-acyl-alpha amino acid or derivatives
  • Quinoline
  • Isoindole or derivatives
  • Indole or derivatives
  • Indole
  • Aralkylamine
  • N-alkylpiperazine
  • Tetrahydropyridine
  • Benzenoid
  • Substituted pyrrole
  • Piperazine
  • Oxazolidinone
  • 1,4-diazinane
  • Aryl halide
  • Aryl bromide
  • Heteroaromatic compound
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Pyrrole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Orthocarboxylic acid derivative
  • Lactam
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Alkanolamine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organobromide
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Cavallotti C, Nuti F, Bruzzone P, Mancone M: Age-related changes in dopamine D2 receptors in rat heart and coronary vessels. Clin Exp Pharmacol Physiol. 2002 May-Jun;29(5-6):412-8. [PubMed:12010185 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  4. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
  5. Lahlou S: Cardiovascular responses to intrathecal dopamine receptor agonists in conscious DOCA-salt hypertensive rats. Fundam Clin Pharmacol. 1999;13(6):624-34. [PubMed:10626749 ]
  6. Lahlou S, Araujo Lima PF, Interaminense LF, Duarte GP: Blunted central bromocriptine-induced tachycardia in conscious, malnourished rats. Pharmacol Toxicol. 2003 Apr;92(4):189-94. [PubMed:12753422 ]
  7. Lahlou S, Lima GC, Leao-Filho CS, Duarte GP: Effects of long-term pretreatment with isoproterenol on bromocriptine-induced tachycardia in conscious rats. Can J Physiol Pharmacol. 2000 Mar;78(3):260-5. [PubMed:10721819 ]
  8. Stefaneanu L, Kovacs K, Horvath E, Buchfelder M, Fahlbusch R, Lancranjan L: Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine. 2001 Apr;14(3):329-36. [PubMed:11444429 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. de Leeuw van Weenen JE, Parlevliet ET, Maechler P, Havekes LM, Romijn JA, Ouwens DM, Pijl H, Guigas B: The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. Biochem Pharmacol. 2010 Jun 15;79(12):1827-36. doi: 10.1016/j.bcp.2010.01.029. Epub 2010 Feb 4. [PubMed:20138024 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. de Leeuw van Weenen JE, Parlevliet ET, Maechler P, Havekes LM, Romijn JA, Ouwens DM, Pijl H, Guigas B: The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. Biochem Pharmacol. 2010 Jun 15;79(12):1827-36. doi: 10.1016/j.bcp.2010.01.029. Epub 2010 Feb 4. [PubMed:20138024 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. de Leeuw van Weenen JE, Parlevliet ET, Maechler P, Havekes LM, Romijn JA, Ouwens DM, Pijl H, Guigas B: The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. Biochem Pharmacol. 2010 Jun 15;79(12):1827-36. doi: 10.1016/j.bcp.2010.01.029. Epub 2010 Feb 4. [PubMed:20138024 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins ...
Gene Name:
HTR2B
Uniprot ID:
P41595
Molecular Weight:
54297.41 Da
References
  1. Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I: Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol. 2008 Oct 10;594(1-3):32-8. doi: 10.1016/j.ejphar.2008.07.040. Epub 2008 Jul 30. [PubMed:18703043 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I: Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol. 2008 Oct 10;594(1-3):32-8. doi: 10.1016/j.ejphar.2008.07.040. Epub 2008 Jul 30. [PubMed:18703043 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I: Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol. 2008 Oct 10;594(1-3):32-8. doi: 10.1016/j.ejphar.2008.07.040. Epub 2008 Jul 30. [PubMed:18703043 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Knight JA, Smith C, Toohey N, Klein MT, Teitler M: Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists. Mol Pharmacol. 2009 Feb;75(2):374-80. doi: 10.1124/mol.108.052084. Epub 2008 Nov 7. [PubMed:18996971 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Fernando H, Halpert JR, Davydov DR: Resolution of multiple substrate binding sites in cytochrome P450 3A4: the stoichiometry of the enzyme-substrate complexes probed by FRET and Job's titration. Biochemistry. 2006 Apr 4;45(13):4199-209. [PubMed:16566594 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  3. Nath A, Grinkova YV, Sligar SG, Atkins WM: Ligand binding to cytochrome P450 3A4 in phospholipid bilayer nanodiscs: the effect of model membranes. J Biol Chem. 2007 Sep 28;282(39):28309-20. Epub 2007 Jun 15. [PubMed:17573349 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113 ]
  2. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267 ]
  3. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
  4. Renaud JP, Davydov DR, Heirwegh KP, Mansuy D, Hui Bon Hoa GH: Thermodynamic studies of substrate binding and spin transitions in human cytochrome P-450 3A4 expressed in yeast microsomes. Biochem J. 1996 Nov 1;319 ( Pt 3):675-81. [PubMed:8920966 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 02:47